National Institute for Infectious Diseases 'L. Spallanzani', IRCCS, Rome, Italy.
University 'Federico II', Department of Clinical Medicine and Surgery, Naples, Italy.
Clin Microbiol Infect. 2020 Jun;26(6):729-734. doi: 10.1016/j.cmi.2020.03.026. Epub 2020 Mar 28.
The 2019 novel coronavirus (SARS-CoV-2) is a new human coronavirus which is spreading with epidemic features in China and other Asian countries; cases have also been reported worldwide. This novel coronavirus disease (COVID-19) is associated with a respiratory illness that may lead to severe pneumonia and acute respiratory distress syndrome (ARDS). Although related to the severe acute respiratory syndrome (SARS) and the Middle East respiratory syndrome (MERS), COVID-19 shows some peculiar pathogenetic, epidemiological and clinical features which to date are not completely understood.
To provide a review of the differences in pathogenesis, epidemiology and clinical features of COVID-19, SARS and MERS.
The most recent literature in the English language regarding COVID-19 has been reviewed, and extracted data have been compared with the current scientific evidence about SARS and MERS epidemics.
COVID-19 seems not to be very different from SARS regarding its clinical features. However, it has a fatality rate of 2.3%, lower than that of SARS (9.5%) and much lower than that of MERS (34.4%). The possibility cannot be excluded that because of the less severe clinical picture of COVID-19 it can spread in the community more easily than MERS and SARS. The actual basic reproductive number (R) of COVID-19 (2.0-2.5) is still controversial. It is probably slightly higher than the R of SARS (1.7-1.9) and higher than that of MERS (<1). A gastrointestinal route of transmission for SARS-CoV-2, which has been assumed for SARS-CoV and MERS-CoV, cannot be ruled out and needs further investigation.
There is still much more to know about COVID-19, especially as concerns mortality and its capacity to spread on a pandemic level. Nonetheless, all of the lessons we learned in the past from the SARS and MERS epidemics are the best cultural weapons with which to face this new global threat.
2019 年新型冠状病毒(SARS-CoV-2)是一种新型人类冠状病毒,在中国和其他亚洲国家呈流行特征传播;世界范围内也有报道。这种新型冠状病毒病(COVID-19)与一种可能导致严重肺炎和急性呼吸窘迫综合征(ARDS)的呼吸道疾病有关。虽然与严重急性呼吸综合征(SARS)和中东呼吸综合征(MERS)有关,但 COVID-19 表现出一些目前尚未完全了解的独特的发病机制、流行病学和临床特征。
综述 COVID-19、SARS 和 MERS 的发病机制、流行病学和临床特征差异。
对 COVID-19 的英文最新文献进行了综述,并与目前关于 SARS 和 MERS 流行的科学证据提取的数据进行了比较。
COVID-19 在临床特征上似乎与 SARS 没有太大区别。然而,其死亡率为 2.3%,低于 SARS(9.5%),远低于 MERS(34.4%)。不能排除 COVID-19 由于其临床症状较轻,比 MERS 和 SARS 更容易在社区中传播。COVID-19 的实际基本繁殖数(R)(2.0-2.5)仍有争议。它可能略高于 SARS 的 R(1.7-1.9),高于 MERS 的 R(<1)。不能排除 SARS-CoV-2 通过胃肠道途径传播,这一点与 SARS-CoV 和 MERS-CoV 假设相同,需要进一步研究。
我们对 COVID-19 还有很多需要了解,尤其是在死亡率及其在大流行层面传播的能力方面。尽管如此,我们过去从 SARS 和 MERS 疫情中吸取的所有经验教训都是应对这一新的全球威胁的最佳文化武器。